Switzerland Launches Zero-Gravity Research Flights to Accelerate Commercial Drug Development
Zurich, Monday, 7 September 2026.
Switzerland’s eighth parabolic campaign launched on September 7, 2026, with over 60 percent of experiments targeting pharmaceutical development, establishing a direct commercial gateway from Zurich to orbit.
Dominance of Pharmaceutical Applications in Microgravity
The current campaign features a total of 18 experiments, with a significant majority dedicated to life sciences and pharmaceutical development [1]. Specifically, 11 of these experiments are directly related to pharmaceuticals, drug development, or enabling biotechnologies, representing approximately 61.111 percent of the total workload [1]. This concentration indicates a strategic pivot toward commercial applications in low Earth orbit, moving beyond purely academic inquiry [1]. Participating entities include Swiss company Prometheus Life Technologies and CSEM, which are testing organoid cultivation systems alongside nine University of Florida teams conducting research ranging from enzyme catalysis to cardiac and skeletal muscle studies [1].
Dominance of Pharmaceutical Applications in Microgravity
Organized by the Center for Space and Aviation Switzerland and Liechtenstein (CSA), the campaign runs from 7 September 2026 to 11 September 2026 at the Switzerland Innovation Park Zurich and Dübendorf Airfield [1]. The facility is utilizing these parabolic flights as an early qualification phase for transferring experiments from ground-based laboratories to commercial activities in low Earth orbit [1]. Prof. Dr. Dr. Oliver Ullrich, Chairman of the Board of Directors at CSA, noted the strategic shift, stating, “We are moving from studying microgravity to using microgravity” [1]. This operational bridge serves both the current International Space Station era and the transition to commercial space stations [2].
Strategic Partnerships and Orbital Infrastructure
To facilitate this transition, the CSA established a fully integrated pathway at the Switzerland Innovation Park Zurich, connecting laboratory preparation through parabolic flight test and qualification to low Earth orbit [2]. This hub provides a practical route to orbital research and development aboard the International Space Station, including three initial free competitive experiment slots provided jointly by the CSA and Starlab Space [2]. Starlab is a U.S.-led global joint venture among Voyager Technologies, Airbus, Mitsubishi Corporation, MDA Space, Palantir Technologies, and Space Applications Services [2]. Through this ecosystem, customers can conduct research aboard the ISS and establish a direct pathway to Starlab once the station becomes operational [2].
Strategic Partnerships and Orbital Infrastructure
International collaboration extends to academic institutions, highlighted by a strategic agreement signed in 2025 between the CSA and the University of Florida for in-space manufacturing and life sciences [1]. Additionally, eight experiments in the current campaign were developed within the Ohio State–Starlab research environment [1]. On 10 September 2026, the CSA is scheduled to sign a Memorandum of Understanding with The Ohio State University covering microgravity research and human health [1][alert! ‘signing status pending’]. On the same date, the CSA intends to expand its international network, though the finalization of these agreements remains pending [1][alert! ‘expansion status pending’].
Long-Term Vision for a European Space Gateway
Looking toward the future, the Dübendorf airfield site close to Zurich is set to develop this gateway into an established European end-to-end system by the end of 2030 [2]. This system will be open to companies, start-ups, and research institutions, integrating ground-based development, flight and microgravity qualification, and direct access to orbital missions [3]. The infrastructure aims to create a transatlantic bridge for business and investment, linking the Swiss hub with the U.S. launch ecosystem [2]. This development reflects broader global investments in private space technology and commercial microgravity testing platforms that are reshaping the aerospace supply chain [1].